MedTrace Logo

Phase 1 Study of DW-0919 & DW-0920 in Healthy Male Volunteers Under Fasting Condition

NCT01606059 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2016-10-12

No results posted yet for this study

Summary

The purpose of this study is to evaluate safety and pharmacokinetics of DW-0919 and DW-0920 in healthy male volunteers under fasting condition.

Conditions

  • Healthy

Interventions

DRUG

DW-0920

Dosage form: Extended release tablet Dosage: 2 tablets

DRUG

DW-0919

Dosage form: Extended release tablet Dosage: 1 tablet

Sponsors & Collaborators

  • Chungnam National University Hospital

    collaborator OTHER

  • Daewon Pharmaceutical Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
20 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-05-31
Primary Completion
2012-06-30
Completion
2012-06-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01606059 on ClinicalTrials.gov